Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • BI 836826 - Leukemia, Lymphocytic, Chronic, B-Cell
    Clinical Study Number 1270.1
    Study Indication Leukemia, Lymphocytic, Chronic, B-Cell
    Product BI 836826
    Generic Name BI 836826
    Lab Code BI 836826
    Clinical Phase I
    Study Title

    A Phase I, open, dose escalation trial with BI 836826 in patients with advanced chronic lymphocytic leukaemia

    Study Document
    Trial synopsis 1270.1 english
  • BI 836826 - Leukemia, Lymphocytic, Chronic, B-Cell
    Clinical Study Number 1270.13
    Study Indication Leukemia, Lymphocytic, Chronic, B-Cell
    Product BI 836826
    Generic Name BI 836826
    Lab Code BI 836826
    Clinical Phase Ib
    Study Title

    An Open-label, Multi-centre, Phase Ib Trial to Determine the Dose of Intravenous BI 836826 in Combination With Oral Venetoclax in Chronic Lymphocytic Leukaemia Patients Who Are Eligible for Treatment With Venetoclax

    Study Document
    Trial statement 1270.13 english
  • BI 836826 - Leukemia, Lymphocytic, Chronic, B-Cell
    Clinical Study Number 1270.15
    Study Indication Leukemia, Lymphocytic, Chronic, B-Cell
    Product BI 836826
    Generic Name BI 836826
    Lab Code
    Clinical Phase Ib
    Study Title

    A Phase Ib, Open label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination with ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

    Study Document
    Trial synopsis 1270.15 english